Sharing ideas that do good

World-class, next-generation Influenza Vaccine Manufacturing Facility to be built in Aus

post-image
The world's second largest influenza vaccine provider will construct a new world-class biotech manufacturing facility in Australia - a $1.8 billion dollar deal in total. Seqirus who will invest $800 million, aims to supply influenza vaccines to Australia and across the globe with the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere. They will also manufacture their proprietary MF59 which is a substance added to some vaccines to improve immune response and reduce the amount of antigen in vaccines. This means that more doses can be manufactured quicker. | https://www.seqirus.com/news/seqirus-will-build-world-class-vaccine-manufacturing-facility
What do you think?

You must be logged in to post a comment.
Comments
Generic placeholder image

By Mel Raassina

16 November 2020

 
5 Like


Related Posts

Healthcare

post-image

New drug for treating melanoma and other cancers
9 April 2021 by Mel Raassina 0 Comments
 
5 Like

Healthcare

post-image

Mining the gut microbiome for Parkinson's
30 March 2021 by Mel Raassina 0 Comments
 
6 Like

Healthcare

post-image

Large-scale cell culture production site in the US to open with Fujifilm as backer
30 March 2021 by Mel Raassina 0 Comments
 
6 Like